Correction to: Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway

Correction to: J Neuroinflammation

https://doi.org/10.1186/s12974-016-0475-0

After the publication of the original article [1], it came to the authors’ attention that there was an error in the originally published version of Fig. 5b. The image of CD4⁺CD25⁺ T cells of the statin-Dex group was unintentionally replaced with the image of CD4⁺CD25⁺ T cells from the control group. The correct version of Fig. 5b is published in this Erratum.

Fig. 5

Statin-Dex treatment increase the number of CD4⁺Foxp3⁺ T cells in lymphocytes. Expressions of CD4⁺CD25⁺ T cells and CD4⁺Foxp3⁺ T cells among lymph node MNC in statin-Dex group, control-Dex group, and control group were detected by FACS. The results showed that statin-Dex treatment increased the percentage of CD4⁺Foxp3⁺ T cells among lymph node MNC when compared with control-Dex and PBS treatments, while there was no difference for the percentage of CD4⁺CD25⁺ T cells. Meanwhile, we did not observe difference in the percentages of CD4⁺CD25⁺ T cells and CD4⁺Foxp3⁺ T cells between control-Dex group and control group (a, b). The results are expressed as mean ± SD (n = 5 rats per group) (*p < 0.05)